This surveillance report was prepared by EUVAC.net, which is a European surveillance network for vaccine-preventable diseases. The network collects data on surveillance systems and selected epidemiological characteristics of vaccine preventable diseases in the EU and other participating countries. It is jointly funded by ECDC and the Statens Serum Institut (Denmark).
The authors assess the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011 (this period included a large outbreak in 2010).
This large population based sero-epidemiological study describes MMR seroprevalence as a whole and calculates independent predictors for seronegativity for measles, mumps and rubella antibodies in Germany.
ECDC convened a meeting of public health experts and successful professionals with experience in management, marketing, campaigning, behaviour change and other professional areas. The purpose of the event was to generate new ideas for promoting measles vaccination in Europe.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
The goal of eliminating rubella and preventing CRS by 2015 could be achieved and maintained adopting a comprehensive approach to ensure high vaccination coverage.
Despite a reduction in pertussis among younger children and infants, rates of pertussis-related sickness and death remain high compared with rates for other vaccine-preventable diseases in England and Wales.
Elimination of rubella and prevention of congenital rubella infection in Europe has been a high priority for the WHO European Regional Office over the past decade. In 2010 the WHO regional committee for Europe renewed its commitment to the elimination of rubella and prevention of CRS with a new target of 2015. For Central Europe to reach the target of rubella elimination and prevention of CRS by 2015, very high vaccine coverage levels need to be maintained and catch-up campaigns continued to address susceptible groups, in particular women of child-bearing age.